The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers

被引：0

作者：

Gane, Edward J. ^{[1
]}

Schwabe, Christian ^{[2
]}

Liu, Jieming ^{[3
]}

Stamm, Luisa M. ^{[3
]}

Kitrinos, Kathryn M. ^{[3
]}

Knox, Steven J. ^{[3
]}

Anderson, Michele ^{[3
]}

Wang, Grace ^{[3
]}

Zomorodi, Katie ^{[3
]}

机构：

[1] Univ Auckland, Auckland, New Zealand

[2] New Zealand Clin Res, Auckland, New Zealand

[3] Assembly Biosci, San Francisco, CA USA

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT-186

引用

页码：S1161 / S1162

页数：2

共 50 条

[1] SAFETY AND PHARMACOKINETICS OF ABI-H3733, A NOVEL 2nd GENERATION HBV CORE PROTEIN INHIBITOR: RESULTS FROM A PHASE 1a STUDY IN HEALTHY VOLUNTEERS
Gane, Edward J.
Schwabe, Christian
Alves, Katia
Evanchik, Marc
Ma, Julie
Zomorodi, Katie
Knox, Steven J.
Stamm, Luisa M.
[J]. HEPATOLOGY, 2021, 74 : 516A - 516A
[2] Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers
Gane, Edward
Schwabe, Christian
Evanhcik, Marc
Ruby, Eric
Liaw, Sandy
Alves, Katia
Colonno, Richard
Lopatin, Uri
[J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E146 - E147
[3] Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in normal healthy volunteers.
Dave, Nimita
Devlin, Marissa
Rodstrom, Jill
Yu, Bei
Foley, Megan
He, Kevin
Rasmussen, Scott
Boral, Andy
Si, Tuan Dong
[J]. CANCER RESEARCH, 2021, 81 (13)
[4] Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
Min, Sherene
Song, Ivy
Borland, Julie
Chen, Shuguang
Lou, Yu
Fujiwara, Tamio
Piscitelli, Stephen C.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 254 - 258
[5] Pregabalin pharmacokinetics and safety in healthy volunteers: Results from two Phase 1 studies
Bockbrader, HN
Hunt, T
Strand, J
Posvar, E
Sedman, A
[J]. NEUROLOGY, 2000, 54 (07) : A421 - A421
[6] PHARMACOKINETICS, SAFETY AND TOLERANCE OF BCD-085, A NOVEL IL-17 INHIBITOR, BASED ON THE RESULTS OF PHASE 1 CLINICAL STUDY IN HEALTHY VOLUNTEERS
Chernyaeva, E.
Eremeeva, A.
Galustyan, A.
Ivanov, R.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 429 - 429
[7] Pharmacokinetics, Safety, and Tolerability of Etrasimod: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Volunteers
Lee, Caroline A.
Tang, Yong
Villa-Caballero, Leonel
Shan, Kevin
Randle, Andrenika
Grundy, John S.
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S550 - S550
[8] Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of Teneligliptin, a New DPP-IV Inhibitor, in Healthy Volunteers
Kumagai, Yuji
Fujita, Tomoe
Kawaguchi, Atsuhiro
Hayashi, Yoshiharu
Kondou, Kazuoki
[J]. DIABETES, 2010, 59 : A193 - A193
[9] Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: preliminary results from a randomized, blinded, Phase 1b study
Gane, Edward J.
Jucov, Alina
Katzarov, Krum
Sandulescu, Oana
Yan, Ran
Kitrinos, Kathryn M.
Liu, Jieming
Zomorodi, Katie
Stamm, Luisa M.
Knox, Steven J.
Anderson, Michele
Wang, Grace
Tsrancheva, Radoslava
Streinu-Cercel, Anca
[J]. JOURNAL OF HEPATOLOGY, 2023, 78 : S1149 - S1150
[10] INTERIM RESULTS OF HBV001, A PHASE 1 STUDY EVALUATING THE SAFETY AND TOLERABILITY OF THERAPEUTIC VACCINATION WITH ChAdOx1-HBV IN HEALTHY VOLUNTEERS AND PATIENTS WITH CHRONIC HEPATITIS B INFECTION
Cargill, Tamsin
Cicconi, Paola
Brown, Anthony
Karanth, Benaka
Chinnakannan, Senthil
Sebastian, Sarah
Bussey, Louise
Eagling-Vose, Elizabeth
Sorensen, Henrik
Evans, Tom
Barnes, Eleanor
[J]. HEPATOLOGY, 2021, 74 : 510A - 511A

← 1 2 3 4 5 →